The SYMPLICITY HTN-3 trial demonstrated unexpectedly large and small blood pressure reductions in the control and renal denervation groups, respectively. Although this study was well designed, it had several weaknesses and the results are inconclusive, with the exception of the positive signal for renal denervation in non-African-American individuals.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Bangalore, S. et al. Prevalence, predictors, and outcomes in treatment-resistant hypertension in patients with coronary disease. Am. J. Med. 127, 71–81.e1 (2014).
Mancia, G. et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J. Hypertens. 31, 1281–1357 (2013).
Bhatt, D. L. et al. A controlled trial of renal denervation for resistant hypertension. N. Engl. J. Med. 370, 1393–1401 (2014).
Krum, H. for the Symplicity HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension 57, 911–917 (2011).
Esler, M. D. et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (the Symplicity HTN-2 trial): a randomised controlled trial. Lancet 376, 1903–1909 (2010).
Mahfoud, F. et al. Reduction in office blood pressure after renal denervation in a large real world patient population with uncontrolled hypertension: interim results from the global SYMPLICITY registry. Presented at the 2014 ACC Scientific Sessions.
O'Brien, E. et al. European society of hypertension position paper on ambulatory blood pressure monitoring. J. Hypertens. 31, 1731–1768 (2013).
Weber, M. A. et al. A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial. Lancet 374, 1423–1431 (2009).
Oxlund, C. S. et al. Low dose spironolactone reduces blood pressure in patients with resistant hypertension and type 2 diabetes mellitus: a double blind randomized clinical trial. J. Hypertens. 31, 2094–2102 (2013).
Mahfoud, F. et al. Ambulatory blood pressure changes after renal sympathetic denervation in patients with resistant hypertension. Circulation 128, 132–140 (2013).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author has received speaker's honoraria from Kona Medical, Medtronic, ReCor Medical, and Rox Medical; grants or research support from Medtronic and Rox Medical; and has acted as an advisory board member for Kona Medical, Medtronic, ReCor Medical, and Rox Medical.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Schmieder, R. How should data from SYMPLICITY HTN-3 be interpreted?. Nat Rev Cardiol 11, 375–376 (2014). https://doi.org/10.1038/nrcardio.2014.70
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrcardio.2014.70
This article is cited by
-
Renal Denervation for Treatment of Hypertension: a Second Start and New Challenges
Current Hypertension Reports (2016)
-
Managing Treatment-Resistant Patients
High Blood Pressure & Cardiovascular Prevention (2015)
-
Ethnicity and sympathetic tone: predictors of the blood pressure response to renal denervation?
Nature Reviews Cardiology (2014)
-
Renal denervation—a valid treatment option despite SYMPLICITY HTN-3
Nature Reviews Cardiology (2014)
-
Where and when Device Therapy May Be Useful in the Management of Drug-Resistant Hypertension
Current Cardiology Reports (2014)
